The current valuation score of Oramed Pharmaceuticals Inc is 8.95, ranking 67 out of 387 in the Biotechnology & Medical Research industry. Its current P/E ratio is 1.61, which is 1523.18% below the recent high of 26.12 and 968.27% above the recent low of -13.97.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.